EUCTR2004-001845-13-IT进行中（未招募）不适用
A Phase II, multicentre, multinational, prospective, randomised, double-blind, placebo controlled study assessing the efficacy and safety of a single application of three doses of Dysport in patients with upper back Myofascial Pain Syndrome (MPS)
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A phase II, multicentre, multinational, prospective, randomised, double-blind, placebo controlled study assessing the efficacy and safety of a single application of three doses of Dysport in patients with upper back myofascial pain syndrome (MPS)EUCTR2004-001845-13-CZBeaufour Ipsen Pharma S.A.S.340
进行中（未招募）
不适用
A phase II, multicentre, multinational, prospective, randomised, double-blind, placebo controlled study assessing the efficacy and safety of a single application of three doses of Dysport in patients with upper back myofascial pain syndrome (MPS)pper back myofascial pain syndrome (MPS)MedDRA version: 7.0Level: PTClassification code 10048780EUCTR2004-001845-13-GBBeaufour Ipsen Pharma S.A.S.340
进行中（未招募）
不适用
A phase II, multicentre, multinational, prospective, randomised, double-blind, placebo controlled study assessing the efficacy and safety of a single application of three doses of Dysport in patients with upper back myofascial pain syndrome (MPS)pper back myofascial pain syndrome (MPS)MedDRA version: 7.0Level: PTClassification code 10048780EUCTR2004-001845-13-DEBeaufour Ipsen Pharma S.A.S.380
已完成
2 期
A Phase II, international, multi-centre, prospective, randomised, parallel-group, double-blind, dose-ranging, placebo-controlled, 12-week, princeps study to assess the efficacy and safety of a one injection cycle with either botulinum toxin type-A (Dysport® 125, 250 or 500 units) or placebo followed by an optional 6-month extension phase in the symptomatic treatment of micturition urgency and frequency in continent female subjects suffering from idiopathic overactive bladder.NL-OMON31902Ipsen Pharmaceuticals30
进行中（未招募）
不适用
A phase II, international, multi-centre, prospective, randomised, parallel-group, double-blind, dose-ranging, placebo-controlled, 12-week, princeps study to assess the efficacy and safety of a one injection cycle with either botulinum toxin Type-A (Dysport® 125, 250 or 500 Units) or placebo followed by an optional 6-month extension phase in the symptomatic treatment of micturition urgency and frequency in continent female subjects suffering from idiopathic overative bladder.Idiopathic overactive bladderMedDRA version: 9.1Level: LLTClassification code 10020853Term: Hypertonic bladderEUCTR2007-002999-34-GBIpsen Limited301